Funding for this research was provided by:
Folkhälsan Research Foundation
Helsinki University Central Hospital Research Funds (TYH2018207)
Wilhelm och Else Stockmanns Stiftelse
Medicinska Understödsföreningen Liv och Hälsa
Novo Nordisk Fonden (NNF OC0013659)
Sigrid Juséliuksen Säätiö
Academy of Finland (299200, 316664)
European Foundation for the Study of Diabetes (Young Investigator Research Award funds, EFSD award supported by EFSD/Sanofi European Diabetes Research Programme in Macrovascular Complications)
Received: 2 August 2022
Accepted: 4 November 2022
First Online: 23 November 2022
: The study protocol was approved by the Ethical Committee of the Helsinki and Uusimaa Hospital District (491/E5/2006, 238/13/03/00/2015, and HUS-3313-2018, July 3rd, 2019) and the participants gave their informed consent before recruitment. This study was performed following the Declaration of Helsinki.
: Not applicable.
: P-H.G. has received investigator-initiated research grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, Medscape, Merck Sharp & Dohme, Mundipharma, Nestlé, Novartis, Novo Nordisk, and Sanofi, and has received lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Merck Sharp & Dohme, Medscape, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc. The remaining authors declare that they have no competing interests.